Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437687 | 0.95 | NR1I2 (0.39) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL29010728 | 0.93 | NR1I2 (0.38) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL25718606 | 0.89 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22363336 | 0.88 | FAAH (0.39) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL28744964 | 0.86 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22692965 | 0.86 | FAAH (0.40) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL25106891 | 0.81 | CYP1A2 (0.35) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7200344 | 0.75 | SIGMAR1 (0.40) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL27512424 | 0.74 | CYP1A2 (0.31) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL23395151 | 0.71 | HMGCR (0.32) | NR1I2HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20180086735-A1 | N-CYCLOALKYL-N-(BIHETEROCYCLYETHYLENE)-(THIO)CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086735-A1 | N-CYCLOALKYL-N-(BIHETEROCYCLYETHYLENE)-(THIO)CARBOXAMIDE DERIVATIVES | CBR3, CYP51A1, CBR1 | CYP1A2 67/4885CYP2D6 446/4885CYP19A1 1435/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | CYP1A2 3438/4885CYP2D6 3350/4885CYP19A1 3722/4885 |
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NOD1, NLRP1 | CYP1A2 954/4885CYP2D6 2264/4885CYP19A1 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.